Figure 1: Time To 80% Or Greater Block Vs. Initial Dose Of Rocuronium Bromide By Age Group (median, 25th And 75th Percentile, And Individual Values) (Rocuronium Fig1)
Rocuronium Bromide Injection, Solution
Product Images NDC 55150-226
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rocuronium Bromide (NDC 55150-226). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2: Duration Of Clinical Effect Vs. Initial Dose Of Rocuronium Bromide By Age Group (median, 25th And 75th Percentile, And Individual Values) (Rocuronium Fig2)
This is a graph depicting the duration of clinical effect of Rocuronium Bromide against the initial dose administered to different age groups. The median, 25th and 75th percentile, as well as individual values, are presented in the graph. There are four age groups represented in the graph: 18-64 years, greater than or equal to 65 years, 3 months to 1 year old, and 11 to 12 years old. The X-axis shows the initial dose and the Y-axis shows the duration of the clinical effect.*
Figure 3: Duration Of Clinical Effect Vs. Number Of Rocuronium Bromide Maintenance Doses, By Dose (Rocuronium Fig3)
The figure shows the relationship between the duration of clinical effect and the number of maintenance doses of Rocuronium Bromide administered, based on the dosage. The x-axis represents the dose number, while the y-axis indicates the duration of clinical effect in minutes. Unfortunately, no numerical values are given to interpret the data, making it not possible to determine any specific conclusion.*
Package Label-principal Display Panel (50 mg per 5 mL (10 mg / mL))
This is a warning for a drug called Rocuronium, which is a paralyzing agent and can cause respiratory arrest. Facilities for artificial respiration must be immediately available when using this drug. The drug should be stored in a refrigerator between 2-8°C and should not be frozen. It is only for intravenous use and comes in a multiple dose vial of 5mL with 50mg per 5mL. The drug should not be used after 60 days of being removed from refrigeration and caution should be taken to use it within the recommended room temperature storage conditions. This drug is only available with a prescription.*
Package Label-principal Display Panel (50 mg per 5 mL (10 mg / mL))
This is a description of a pharmaceutical product named Rocuronium Bromide Injection. It is a sterile, nonpyrogenic solution for intravenous use only. Each mL of the injection contains 10 mg of Rocuronium Bromide USP. It is a paralyzing agent that could cause respiratory arrest. The facilities that use this product should have immediate availability for artificial respiration. The recommended dosage is available in the prescribing information enclosed. The injection should be stored under refrigeration between 2 to 8 degree Celsius and should not be frozen. The product has a shelf life of 60 days when stored at room temperature after removal from refrigeration, and 30 days once the vial is opened. The valve stoppers are not made with natural rubber latex.*
Package Label-principal Display Panel (100 mg per 10 mL (10 mg / mL))
This is a warning for a medication indicated as a paralyzing agent that can cause respiratory arrest, and facilities for artificial respiration should be immediately available. The medication is called Rocuronium and is contained in a 10mL multiple-dose vial that should be stored in a refrigerator between 2°C to 8°C (36°F to 46°F), and should not freeze. After removal from refrigeration to room temperature, the medication can be used within 50 days if kept at 25°C/77°F, or within 30 days if the vial has been opened. The manufacturer is AuroMedics Pharma LLC, located in E. Windsor, NJ, and the medication was made in India.*
Package Label-principal Display Panel (100 mg per 10 mL (10 mg / mL))
This seems to be the description of a medication called Rocuronium Bromide Injection, which is a paralyzing agent for intravenous use only. The medication is distributed by AuroMedics Pharma LLC and is available in 10 x 10 mL multiple dose vials. Each mL contains 10 mg of rocuronium bromide USP, equivalent to 8.69 mg of rocuronium, and 2 mg of sodium acetate. The medication should be stored under refrigeration and not be frozen. It is important to read the enclosed prescribing information for the usual dosage. Facilities must be immediately available for artificial respiration in case the medication causes respiratory arrest.*
Package Label-principal Display Panel (Peel-off Label)
Rocuronium Bromide Chemical Structure (Rocuronium Str)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
